论文部分内容阅读
本文评价长期口服尼卡地平对哮喘病人的1秒钟用力呼气容积(FEV_1)、动脉氧分压(PaO_2)和降低基础FEV_120%所需组胺剂量 (PD_((20his)))的可能影响。10例非重症哮喘病人。口服尼卡地平20mg,每日3次,共3个月。在此期间治疗药物继续使用。结果:尼卡地平治疗3个月后,FEV_1与治疗前相比变化不大;PaO_2较治疗前降低(8.35±0.76kpa→8.295±0.74 kpa,P<0.02)但无临床意义;PD_(20his)较治疗前显著增加(3.06±0.54mg/ml→3.24±0.62 mg/ml,P<0.01)。研究期间,仅2例病人有轻微头痛,
This article evaluates the potential impact of long-term oral nicardipine on asthmatic patients with FEV 1, PaO 2, and histamine dose required to reduce basal FEV_120% (PD_ (20his)) . 10 cases of non-severe asthma patients. An oral nicardipine 20mg, 3 times a day for a total of 3 months. During this period the treatment drug continues to be used. Results: After 3 months of treatment with nicardipine, FEV_1 did not change much before treatment; PaO_2 was lower than before treatment (8.35 ± 0.76kPa → 8.295 ± 0.74kpa, P <0.02) Which was significantly higher than that before treatment (3.06 ± 0.54mg / ml → 3.24 ± 0.62 mg / ml, P <0.01). During the study, only 2 patients had mild headaches,